Every material Form 8-K PTC Therapeutics has filed with the SEC since January 13, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PTC Therapeutics' Board of Directors authorized a share repurchase program allowing the company to buy back up to $500 million of its common stock, subject to market conditions. The filing does not give a timing or schedule for purchases, and the company says repurchases will be made at management's discretion and reported in its Form 10-Q and Form 10-K filings.
Authorization: up to $500 million of outstanding common stock, announced November 3, 2026
Repurchases may be made from time to time at management's discretion, subject to market conditions
Methods include open-market transactions with pre-set trading plans, privately negotiated deals, and accelerated share repurchases
CEO Matthew B. Klein said the program leaves financial flexibility to support existing programs and pursue potential business development transactions
PTC Therapeutics reported third-quarter 2026 total revenue of $358 million, up from $211.0 million a year earlier, and raised its full-year 2026 total and product revenue guidance. The company also recorded a net loss of $51.7 million, compared with net income of $15.9 million in the prior-year quarter, after a $111.0 million acquired in-process R&D charge for the ST-920 Fabry gene therapy.
Q3 2026 total revenue was $357.8 million, versus $211.0 million in Q3 2025; Sephience net product revenue was $181.9 million.
Net loss was $51.7 million ($0.62 per share) versus net income of $15.9 million a year earlier, including the $111.0 million ST-920 charge.
Full-year 2026 product revenue guidance was raised to $960 to $990 million from $850 to $950 million; total revenue guidance is $1.29 to $1.32 billion.
Cash, cash equivalents and marketable securities were $2,127.9 million on September 30, 2026.
PTC Therapeutics entered an asset purchase agreement on August 25, 2026 to acquire ST-920, an AAV gene therapy candidate for Fabry disease, from bankrupt Sangamo Therapeutics. The deal carries a $111 million upfront payment plus up to $100 million in contingent milestones tied to FDA approval, and closing requires Bankruptcy Court approval, which is scheduled for a hearing on September 10, 2026.
Upfront payment of $111 million, plus up to $100 million in contingent milestones ($80 million on accelerated approval and $20 million on full approval)
Acquisition is subject to Bankruptcy Court approval (hearing scheduled September 10, 2026) and Hart-Scott-Rodino waiting period expiration
Either party may terminate if closing has not occurred by October 15, 2026, subject to specified exceptions
Representations and warranties do not survive closing and there is no indemnification for breaches
PTC Therapeutics reported second-quarter 2026 total revenue of $360.5 million, up from $178.9 million a year earlier, and net income of $83.5 million, compared with a net loss of $64.8 million in the prior-year quarter. The company raised its 2026 product revenue guidance to $850 million to $950 million and its total revenue guidance to $1.18 billion to $1.28 billion, and it also appointed Hege Sollie-Zetlmayer, its former Chief Human Resources Officer, to the board.
Q2 2026 total revenue was $360.5 million, including $238.8 million of net product revenue and a $50.0 million Novartis milestone recorded as collaboration revenue.
Full-year 2026 product revenue guidance was raised to $850 million to $950 million from $750 million to $850 million.
Sephience generated $151.3 million in Q2 2026 net product revenue; cash, cash equivalents and marketable securities were $2.2 billion as of June 30, 2026.
Hege Sollie-Zetlmayer was appointed to the board effective July 28, 2026, filling a vacancy.
PTC Therapeutics completed a private offering of $550 million in 0.0% convertible senior notes due June 15, 2031, including the full $50 million option exercised by the initial purchasers. The company is using about $328.8 million of the estimated $535.5 million net proceeds to repurchase $222.0 million of its existing 1.50% convertible notes due 2026, leaving $55.5 million of those notes outstanding, which shifts its debt toward the new notes for shareholders.
Notes: $550 million principal, 0.0% interest, maturing June 15, 2031
Initial conversion price of approximately $107.48 per share (9.3042 shares per $1,000 principal)
Estimated net proceeds of $535.5 million; $328.8 million used to repurchase $222.0 million of 2026 notes
Existing 1.50% convertible notes outstanding after repurchases: $55.5 million
PTC Therapeutics director Alethia Young resigned from the board effective June 8, 2026, citing commitments to other work activities and not any disagreement with the company. She will remain as an advisor under a consulting agreement running through June 8, 2027, for a monthly fee of $4,166.67.
Alethia Young resigned from the board of directors effective June 8, 2026.
Resignation was stated to be due to her need to focus on other work commitments, not a disagreement with the company.
Consulting agreement runs June 8, 2026 through June 8, 2027, at $4,166.67 per month (Exhibit 10.1).
PTC Therapeutics reported first quarter 2026 total revenue of $272.6 million and a net loss of $2.8 million, or $0.03 per share, compared with net income of $866.6 million a year earlier. The year-earlier figure included $986.2 million of collaboration and license revenue, while net product revenue rose 47% to $225.6 million. The company raised its full-year 2026 product revenue guidance to $750 million to $850 million.
Total revenue was $272.6 million in Q1 2026, versus $1,176.1 million in Q1 2025, which included $986.2 million of collaboration and license revenue.
Net product revenue was $225.6 million, up 47% from $153.4 million a year earlier; Sephience revenue was $124.6 million.
Net loss was $2.8 million, or $0.03 per share, compared with net income of $866.6 million in Q1 2025.
Full-year 2026 total product revenue guidance was raised to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion; GAAP R&D and SG&A expense guidance was unchanged at $775 million to $815 million.
PTC Therapeutics appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director. Ms. Chutter retired from Morgan Stanley in February 2026 after more than 40 years in healthcare investment banking, and she received standard outside director pay and equity grants.
Appointed March 24, 2026, as a Class I director with a term expiring at the 2026 annual meeting
Receives a $50,000 base annual retainer under the outside director compensation policy
Initial grant of 3,475 stock options and 4,000 restricted stock units, plus a pro-rated 2026 annual grant of 2,896 options and 3,333 RSUs
Previously Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley; company says she was involved in about $80 billion of capital raising and $85 billion of strategic transactions
PTC Therapeutics reported fourth-quarter 2025 total revenue of $164.7 million, down from $213.2 million a year earlier, and a net loss of $135.0 million, wider than the $65.9 million loss in the prior-year quarter. For the full year, total revenue rose to $1,730.7 million and net income was $682.6 million, but both figures were lifted by a $998.4 million Novartis votoplam collaboration and license revenue item. The company also issued 2026 total product revenue guidance of $700 million to $800 million.
Q4 2025 total revenue was $164.7 million versus $213.2 million in Q4 2024; Q4 net loss was $135.0 million versus $65.9 million.
Q4 results include a $98.6 million change in the Translarna France sales allowance estimate, a life-to-date adjustment.
Full-year 2025 net income was $682.6 million, or $7.78 per diluted share, versus a net loss of $363.3 million in 2024.
2026 guidance: total product revenue of $700 million to $800 million, with the majority expected from Sephience.
PTC Therapeutics said preliminary, unaudited 2025 total product and royalty revenue was about $823.4 million, which it describes as exceeding its guidance. The company also guided to 2026 total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue, and to GAAP R&D and SG&A expense of $775 million to $815 million. Final 2025 results remain subject to the year-end audit.
Unaudited 2025 total product and royalty revenue of about $823.4 million; unaudited total product revenue of about $587.8 million
Sephience unaudited Q4 2025 net revenue of about $92.5 million, including $81.6 million in the US and $10.9 million ex-US
2026 guidance: total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue
2026 GAAP R&D and SG&A expense guidance of $775 million to $815 million, or $680 million to $720 million excluding about $95 million of non-cash stock-based compensation
PTC Therapeutics sold its retained interest in its Evrysdi royalty stream to Royalty Pharma Investments 2019 ICAV on December 29, 2025, for $240.0 million in upfront cash. The company also may receive three additional $20.0 million payments, each tied to royalty payments exceeding set thresholds in 2027, 2028 and 2029, and it no longer owns any part of the royalty.
Upfront cash consideration of $240.0 million paid to PTC Therapeutics on December 29, 2025
Three potential $20.0 million payments, conditioned on Assigned Royalty Payments above $347.0 million (2027), $363.0 million (2028) and $379.0 million (2029)
Retained interest sold was 9.5111% of the Royalty before the 2020 Assigned Royalty Cap is met and 16.6666% after; PTC now owns 0% of the Royalty
PTC Therapeutics reported third-quarter 2025 total revenue of $211.0 million, up from $196.8 million a year earlier, and net income of $15.9 million, compared with a net loss of $106.7 million in the same period of 2024. The company narrowed its full-year 2025 total revenue guidance to $750 million to $800 million and said the Sephience launch began in the US and Europe, though net product revenue for Translarna and Emflaza declined year over year.
Q3 2025 total revenue was $211.0 million, compared with $196.8 million in Q3 2024.
Q3 2025 net income was $15.9 million, or $0.20 per diluted share, versus a net loss of $106.7 million in Q3 2024.
Sephience generated $19.6 million in Q3 2025 global revenue, with 521 US patient start forms as of September 30, 2025.
Translarna net product revenue fell to $50.7 million from $72.3 million, and Emflaza fell to $35.2 million from $51.9 million.
On August 5, 2025, PTC Therapeutics entered a Rights Satisfaction Agreement under which former Censa Pharmaceuticals securityholders gave up their rights to payments based on sepiapterin net sales. The company paid about $225 million in cash at closing and may owe up to $500 million more in milestone payments. Other obligations under the 2020 Merger Agreement remain in effect.
At closing, PTC paid about $225.0 million in cash to participating former Censa securityholders, who held about 90% of Censa's equity.
Participants forfeited net sales payments of 8% on sales up to $250.0 million, 10% on sales from $250.0 million to $500.0 million, and 12% on sales above $500.0 million.
Additional milestone payments of about $90.0 million each, up to $500.0 million in total, are tied to aggregate net sales thresholds from $3.0 billion to $11.0 billion.
The agreement was signed and closed simultaneously, and the full text will be filed with the Form 10-Q for the quarter ending September 30, 2025.
PTC Therapeutics reported second-quarter 2025 total revenue of $178.9 million, down from $186.7 million a year earlier, while its net loss narrowed to $64.8 million from $99.2 million. The company also reaffirmed no prior guidance in this filing but gave full-year 2025 revenue guidance of $650 million to $800 million, and said Sephience received FDA approval on July 28, 2025.
Q2 2025 total revenue $178.9 million vs. $186.7 million in Q2 2024; net product revenue $118.3 million vs. $133.2 million
Q2 2025 net loss $64.8 million, or $0.83 per share, vs. net loss of $99.2 million, or $1.29 per share, in Q2 2024
Full-year 2025 revenue guidance of $650 million to $800 million
Agreed to buy the Sephience sales obligation owed to former Censa shareholders for a $225 million upfront payment; cash and marketable securities were $1,989.2 million at June 30, 2025
PTC Therapeutics reported first quarter 2025 results, with total revenue of $1,176.1 million and net income of $866.6 million, compared with a net loss of $91.6 million a year earlier. The results were driven by a $986.2 million license and collaboration payment from Novartis for PTC518, while net product and royalty revenue fell to $189.9 million from $208.8 million. The company narrowed its full-year 2025 revenue guidance to $650 million to $800 million.
Total revenue was $1,176.1 million, versus $210.1 million in the first quarter of 2024, including $986.2 million tied to the PTC518 license with Novartis, which closed in January 2025.
Net product and royalty revenue was $189.9 million, down from $208.8 million a year earlier.
Net income was $866.6 million, or $10.04 per diluted share, compared with a net loss of $91.6 million, or $1.20 per share, in the first quarter of 2024.
Full-year 2025 revenue guidance was narrowed to $650 million to $800 million; cash and marketable securities were $2,027.2 million as of March 31, 2025.
PTC Therapeutics reported fourth-quarter and full-year 2024 results. Revenue fell from a year earlier, while the net loss narrowed, with a $99.9 million gain on sale of a priority review voucher offsetting part of a $159.5 million intangible asset impairment. The company guided full-year 2025 total revenue to between $600 million and $800 million.
Q4 2024 total revenue was $213.2 million, versus $307.1 million in Q4 2023; full-year 2024 revenue was $806.8 million, versus $937.8 million in 2023.
Q4 2024 net loss was $65.9 million, or $0.85 per share, versus $155.8 million, or $2.06 per share, in Q4 2023.
Q4 2024 results include a $159.5 million intangible asset impairment and a $99.9 million gain on sale of a priority review voucher.
2025 guidance: total revenue of $600 million to $800 million; cash, cash equivalents and marketable securities were $1,139.7 million on December 31, 2024.
PTC Therapeutics reported preliminary, unaudited 2024 total revenue of approximately $814 million, which the company said exceeded its guidance, and gave 2025 total revenue guidance of $600 million to $800 million. The 2025 range sits below the 2024 preliminary figure, and the 2024 numbers remain subject to the year-end audit.
Unaudited 2024 total net revenue of approximately $814 million; net product revenue approximately $601 million
Translarna approximately $340 million and Emflaza approximately $207 million in unaudited 2024 net product revenue; Evrysdi royalty revenue approximately $211 million
2025 guidance: total revenue $600 million to $800 million; GAAP R&D and SG&A expense $805 million to $835 million
Results will be presented at the J.P. Morgan Healthcare Conference on January 13, 2025, after which the company enters a quiet period
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PTC Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →